Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18594710 | 0.94 | CA2 (0.31) | SLC1A2SLC1A1CA2 | |
| SCHEMBL20992224 | 0.86 | — | — | |
| SCHEMBL26153449 | 0.84 | GRIK1 (0.32) | GRIK1GRIK2SLC1A2SLC1A1LMNA | |
| SCHEMBL23801160 | 0.78 | — | — | |
| SCHEMBL26153413 | 0.78 | — | — | |
| SCHEMBL26836478 | 0.76 | — | — | |
| SCHEMBL20849995 | 0.74 | CA2 (0.38) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL22031182 | 0.74 | — | — | |
| SCHEMBL20870229 | 0.71 | MAOB (0.30) | — | |
| SCHEMBL21756760 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248842-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | AbTis Co., Ltd. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230158167-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | AbTis Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248842-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | EEA1, CD47, FCGR2A | GRIK1 4516/4885GRIK2 4326/4885SLC1A2 1956/4885 |
| US-20230158167-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | EEA1, CD47, FCGR2A | GRIK1 4516/4885GRIK2 4326/4885SLC1A2 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.